Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Friday was good news for Eli Lilly (LLY 1.35%) and Viking Therapeutics (VKTX 1.83%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug,
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...
Eli Lilly just gave investors several reasons to cheer.
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback